Oleg Gluz

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Oleg Gluz, Ulrike Nitz, Matthias Christgen et al. · Journal of Clinical Oncology · 2016 · 366 citations

Medicine, Oncology, Breast Oncology +16

Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade

Philipp Müller, Matthias Kreuzaler, Tarik A. Khan et al. · Science Translational Medicine · 2015 · 335 citations

Medicine, Oncology, Pharmacology +17

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Zuzana Kos, Elvire Roblin, Rim S. Kim et al. · npj Breast Cancer · 2020 · 206 citations · Full text

Medicine, Oncology, Pathology +16

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Breast Cancer Research and Treatment · 2017 · 190 citations · Full text

Medicine, Oncology, Breast Oncology +16

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Annals of Oncology · 2017 · 172 citations

Medicine, Oncology, Pharmacology +17